Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab in HCC
NCT03006926Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events up to 50.2 months, Dose Limiting Toxicities and 2 more. Started Feb 2017; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03006926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006926.